CheckMate 214 🔸Durable-long-term efficacy with Nivo-IPI 🔸mFU 67.7 months 🔸mOS: 55.7 months (48% @5Y) 🔸After 3 years the probability of remaining alive for an additional 2 years ↗️ with NIVO+IPI regardless of IMDC ACS Journal Cancer OncoAlert Toni Choueiri, MD acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

Stong 5-yr data just published Kidney Cancer

Important study published. Leibovich and GRANT validated in ccRCC and non-ccRCC nationwide #kidneycancer cohort. Leibovich outperformed GRANT in predicting recurrence-free survival and should remain standard approach to risk stratify patients. @oncoalert doi.org/10.1111/iju.14…

Our IMDC paper outlining #cabozantinib activity post #immunotherapy combination treatment in #kcsm #kidneycancer is out in Elsevier Clinical Genitourinary Cancers..1/6🧵 clinical-genitourinary-cancer.com/article/S1558-…

Our 30-month #KYN564 adjuvant RCC trial is published The Lancet Oncology —led by Tom Powles, presented #GU22 ASCO —Note HR 0.63 improved from 0.68, all subgroups HR<1, AND if we remove M1NED/N+/T4=> HR 0.68. Still significant/clinically relevant OncoAlert sciencedirect.com/science/articl…

Mid week reset! Tyler Seibert MD PhD Adam Sharp Toni Choueiri, MD

Great summary Sumanta K. Pal, MD, FASCO on adjuvant therapy in #renalcellcarcinoma

#ESMO22 Presidential symposium - adjuvant nivo/ipi in #RCC by Robert Motzer MD: - 15% pT2a g3/4, pT2b - 5% sarcomatoid (pdl1 status pending) - placebo arm 24-mos DFS rate 74% (note 67% in KN-564) - 1 in 3 d/c due to drug tox Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Bradley McGregor OncoAlert

A waterfall plot or a tidal wave 🌊???? 🤩 😯 99% pathologic response with nivo/ipi in dMMR CRC and NO disease recurrences!! #ESMO22 ⁦ESMO - Eur. Oncology⁩ ⁦Myriam Chalabi⁩

Awesome discussion!

About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot

Very excited to see our work on molecular analysis in Clear Cell & Non-Clear Cell Real-World #Renal Cell Carcinoma just published in Acta Oncologica Thanks to great collaborative effort w co-authors doi.org/10.1080/028418… OncoAlert Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Brian Rini, MD Torben Steiniche

The new Prime Minister of Italy. Wow.

content.jwplatform.com/previews/sy7Ae…

Cytoreductive nephrectomy associated with longer OS in patients with #mRCC treated with immune checkpoint inhibitor (ICI) therapy in any line of therapy. A multicenter retrospective cohort study of 367 patients (CN+ST 232, ST alone 135). sciencedirect.com/science/articl…

I thought only astronauts, bond villains and tech billionaires appeared in TIME magazine. Some people are all 3 but David McDermott is certainly none of the above and still made it! Uromigos gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Flere kvitter, når prisen på cigaretter ryger i vejret. Men prisen skal hoppe, så det kan mærkes - ellers har det ingen effekt. Så hjælp Sophie Løhde og sundheden, Jeppe Bruus: Sæt prisen højt op, så vi kan få en #røgfrifremtid #dkpol #sundpol altinget.dk/sundhed/artike…

Any suggestions for a training scheme Howard Gurney ?

Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Tom Powles Robert Motzer MD Hans Hammers

Well-written and insightful paper every oncologist and clinician with frontline clinical workload should read - before burnout